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Abstract
The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail.
We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were
detected in 38.7% of patients and were associated with age, histological subtype as well as mitotic rate. The mutational rate
was 36.7% in patients with disease-free course and 51.7% in those with subsequent distant metastasis (p = 0.031). No
difference in overall survival (p = 0.119) but a trend for worse distant-metastasis-free survival (p = 0.061) was observed in
BRAF mutant compared to BRAF wild-type patients. Independent prognostic factors for overall survival were tumor
thickness, mitotic rate and ulceration. An interesting significant prognostic impact was observed in patients with tumor
thickness of 1 mm or less, with the mutation present in 6 of 7 patients dying from melanoma. In conclusion, no significant
survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma but an
increasing impact of the mutational status was observed in the subgroup of patients with tumor thickness of 1 mm or less.
A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger
studies.
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Introduction
The mitogen-activated protein kinase (MAPK) signaling path-
way is constitutively activated by BRAF-V600 tumor mutations
and leads to enhanced mitotic activity [1,2]. Blocking in BRAF-
V600 mutant patients by specific inhibitors leads to a high rate of
clinical responses and an improved survival of melanoma patients
[3–5]. Nevertheless, the prognostic relevance of BRAF mutations
in the natural course of disease is controversial [6–20]. A trend
towards worse survival of metastatic patients with BRAF mutation
was found in three patient cohorts [7–9]. Similarly, a worse
prognosis of metastatic patients with BRAF or NRAS tumor
mutations [10] and of patients with BRAF mutant tumors after
treatment with temozolomide and bevacizumab [11] was reported
before. In contrast, Edlundh-Rose et al. did not find any
association between the tumor NRAS or BRAF genotype and
survival in a metastatic setting [12]. Two independent studies
reported that a BRAF tumor mutation is an unfavorable prognostic
factor for stage III patients after resection of loco-regional
metastases [13,14] but others failed to show any negative
association with outcome in a similar clinical situation [15]. In
non-metastasized patients with primary melanoma, no impact on
prognosis was observed thus far in four studies including up to 115
patients [10,16–18]. A recently published meta-analysis of four
studies including mainly metastatic patients reported an 1.7-fold
increased risk of dying from melanoma for BRAF mutant patients
relative to wild-type patients [21].
The aim of the present study was to investigate the prognostic
impact of BRAF-V600 tumor mutations in patients with
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e86194
non-metastasized cutaneous melanoma after excision of the
primary tumor.
Materials and Methods
Ethics statement
All patients had given their written informed consent to have
their data recorded by the Central Malignant Melanoma Registry
(CMMR). This study was approved by the Ethics Committee,
University of Tu¨bingen (approval 413/2012BO2).
Patients
Patients with invasive cutaneous melanoma treated at the
University Department of Dermatology in Tu¨bingen, Germany,
were identified in the Central Malignant Melanoma Registry
(CMMR) database [22]. All patients with initial excision between
1989 and 2006 and available formalin-fixed paraffin-embedded
tissue of the primary tumor were included. Data obtained for each
patient were gender, age, and the date and cause of death, if
applicable. Moreover, time points of initial diagnosis, occurrence
of the first distant metastasis, and last follow-up were collected.
Histopathologic data of the primary melanoma comprised
Breslow’s tumor thickness, Clark’s level of invasion, ulceration,
subtype (superficial spreading melanoma [SSM], nodular mela-
noma, lentigo maligna melanoma [LMM], acral lentiginous
melanoma [ALM]), and mitoses per mm2. Only patients with
non-metastasized primary cutaneous melanoma at time of initial
diagnosis were included (stages I and II).
Sequencing
Microdissection of formalin-fixed paraffin-embedded tumor
tissue was performed to obtain at least 50% tumor cells. After
digestion by proteinase K an amplicon containing the BRAF codon
600 was amplified by a polymerase-chain-reaction (PCR) assay
using forward primer 59-tcataatgcttgctctgatagga-39 and reverse
primer 59-ccaaaaatttaatcagtgga-39. PCR products were analyzed
on an agarose gel and purified using USB ExoSAP-IT
(Affymetrix, Santa Clara, CA). Sanger sequencing was performed
in reverse direction and sequences were analyzed with Mutation
Surveyor Version 3.20 (SoftGenetics, State College, PA). For all
samples which could not be clearly classified as mutant or wild-
type, PCR and sequencing was repeated.
Statistics
The survival times were calculated as follows: Overall survival
from the date of the initial diagnosis to the date of last follow-up or
death; stage IV survival from the first occurrence of distant
metastasis to the date of last follow-up or death; distant metastasis-
free survival (DMFS) from the date of the initial diagnosis to the
time point of the first occurrence of distant metastasis. Only deaths
due to melanoma were considered, whereas patients who died
from other cause were censored at the date of death. In three
patients who died due to melanoma, the exact date of first
occurrence of distant metastases was not available, and the date of
distant metastasis was estimated to be 9 months before the
melanoma related death, which is the median overall survival
time. Estimates of cumulative survival probabilities according to
Kaplan-Meier were described together with 95%-confidence
intervals and compared using log rank tests. Cox regression
analyses were used to determine the independent effects of
prognostic factors. All variables were considered in Cox regression
analyses and patients with missing data were excluded. Models
were established using backward and forward stepwise procedures.
Remaining non-significant factors were assessed for potential
confounding effects. Changes in the estimates of factors in a model
by more than 5% were taken as indicative for confounding.
Results of the Cox regression models were described by hazard
ratios (HR) together with 95%-confidence intervals, and p-values
were based on the Wald test. All Chi square tests were performed
2-sided using Fisher’s exact tests. Throughout the analysis,
Figure 1. Rate of BRAF-V600mutations in patients with tumor thickness of 1 mm or less (grey bars) or more than 1 mm (black bars)
according to age (left), histological subtype (middle), and mitotic rate (right). SSM – superficial spreading melanoma; NM – nodular
melanoma; LMM – lentigo maligna melanoma; ALM – acral lentiginous melanoma.
doi:10.1371/journal.pone.0086194.g001
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p-values of less than 0.05 were considered statistically significant.
All analyses were carried out using SPSS Version 21 (IBM SPSS,
Chicago, Illinois, USA).
Results
Patients
437 of 451 patients (97%) with successful sequencing were
further analyzed. Median age was 57 years (interquartile range
46–67 years) and 52.8% were male. The stage at initial diagnosis
according to AJCC was IA in 38.2%, IB in 42.8%, IIA in 12.2%,
IIB in 5.1%, IIC in 1.8% of patients, and unknown in two cases
because mitotic rate was not available. During follow-up, 58 of 437
patients (12.6%) developed distant metastasis and 52 (11.9%) died
from melanoma. Median follow-up was 93 months. None of the
patients received treatment with BRAF or MEK inhibitors during
follow up. A BRAF-V600 tumor mutation was detected in 169
patients (38.7%). 150 patients (88.8%) had V600E, 18 (10.6%)
V600K, and 1 (0.6%) V600R mutations.
Clinicopathologic associations according to mutational
status
Associations between the rate of BRAF tumor mutations and
demographic, clinical, or histopathologic characteristics are
presented in Table 1. The BRAF mutational status was strongly
associated with age. While the rate of BRAF mutant melanoma
was 75% in patients younger than 30 years (n = 15) it was only
19% in patients aged 70 years or more (n = 84). This inverse
correlation between BRAF-V600 mutations and age was stronger
among patients with a tumor thickness of 1 mm or less (p,0.001)
compared to those with thick primary melanomas (p = 0.034,
Figure 1, Table 2). Furthermore, an association with the
histological subtype was observed (p,0.001). The majority of
nodular melanomas were BRAF-V600 mutants (57%); the rate was
also high in patients with SSM (43%) but lower in ALMs (30%). In
Table 1. Association of BRAF mutation status with clinicopathological parameters.
Characteristic Rate Mutant Mutant Wild type p-value1
All patients 38.7% 169 268
Gender 0.844
Male 39.3% 90 139
Female 38.0% 79 129
Age ,0.001
,50 years 53.4% 70 61
50–59 years 39.3% 42 65
60–69 years 35.7% 41 74
$70 years 19.0% 16 68
Ulceration 0.338
Yes 45.7% 21 25
No 37.9% 148 243
Tumor thickness 0.190
#0.50 mm 30.2% 29 67
0.51–0.75 mm 33.0% 30 61
0.76–1.00 mm 46.2% 24 28
1.01–2.00 mm 43.8% 60 77
2.01–4.00 mm 42.2% 19 26
.4.00 mm 43.8% 7 9
Histological subtype ,0.001
SSM 43.0% 141 187
NM 57.7% 15 11
LMM 5.8% 3 49
ALM 30.0% 9 21
Clark level 0.277
I–III 36.2% 88 155
IV or V 41.8% 81 113
Mitoses/mm2 0.038
,1 33.2% 72 145
$1 43.0% 93 123
1p-values are results of Chi-square tests.
doi:10.1371/journal.pone.0086194.t001
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contrast, a BRAF-V600 mutation was rarely observed in LMM
(6%). The detection of at least 1 mitosis/mm2 was associated with
mutant BRAF in the entire cohort of patients (p = 0.038) and in
patients with a tumor thickness of more than 1 mm (p= 0.046) but
not in those with thin primary melanomas (p = 1.000, Table 2). No
association with tumor BRAF mutations was observed for gender,
Clark level, ulceration, and tumor thickness. The mutational
rate was 36.7% in 379 patients with disease-free course during
follow-up and 51.7% in 58 patients with subsequent distant
metastasis (p = 0.031).
Survival Analysis
In univariate analysis, tumor thickness, Clark level, ulceration,
histopathologic subtype, and mitotic rate were associated with
overall survival (all p,0.001). The factors indicating worst
prognosis with 10-year survival rates below 50% were a tumor
thickness of at least 4 mm (42.9%) and the presence of ulceration
(45.1%). In contrast, less than 1 mitosis/mm2 and a tumor
thickness of 1 mm or less were associated with more than 95%
survival probability ten years after initial diagnosis. In Cox
regression analysis tumor thickness, ulceration and mitotic rate
independently predicted survival (Table 3). A tumor thickness of
greater than 4 mm or greater than 2 mm had strongest negative
impact on overall survival with a hazard ratio (HR) of 4.7
(p = 0.035) or 4.6 (p = 0.010), respectively, followed by ulceration
(HR 3.6, p,0.001) and a rate of at least 1 mitosis/mm2 (HR 2.9,
p = 0.028). No association of overall survival with the tumor
BRAF-V600 mutational status was observed (p = 0.119; Figure 2A).
No differences in overall survival were detected according to age
or gender.
There was a trend for unfavorable DMFS in patients with BRAF
mutant vs. wild-type melanoma (p = 0.061; Figure 2B). 17.8% of
patients with BRAF mutant tumors but only 10.4% wild-type
Table 2. Association of BRAF mutational status with clinicopathological parameters stratified according to tumor thickness.
Tumor thickness #1 mm (n=239) Tumor thickness .1 mm (n=198)
Characteristic Rate Mutant Mutant Wild type p-valuea Rate Mutant Mutant Wild type p-valuea
All patients 34.7% 83 156 43.4% 86 112
Gender 0.419 0.253
Male 32.2% 39 82 47.2% 51 57
Female 37.3% 44 74 38.9% 35 55
Age ,0.001 0.034
,50 years 50.0% 43 43 60.0% 27 18
50–59 years 37.9% 22 36 40.8% 20 29
60–69 years 27.6% 16 42 43.9% 25 32
$70 years 5.4% 2 35 29.8% 14 33
Ulceration 0.545 0.605
Yes 0.0% 0 2 47.7% 21 23
No 35.0% 83 154 42.2% 65 89
Tumor thickness 0.143 1.000
#0.50 mm 30.2% 29 67
0.51–0.75 mm 33.0% 30 61
0.76–1.00 mm 46.2% 24 28
1.01–2.00 mm 43.8% 60 77
2.01–4.00 mm 42.2% 19 26
.4.00 mm 43.8% 7 9
Histological subtype ,0.001 0.001
SSM 39.7% 81 123 48.4% 60 64
NM 0 0 57.7% 15 11
LMM 3.3% 1 29 9.1% 2 20
ALM 20.0% 1 4 32.0% 8 17
Clark level 0.135 0.159
I–III 32.7% 66 136 53.7% 22 19
IV or V 45.9% 17 20 40.8% 64 94
Mitoses/mm2 1.000 0.046
,1 34.1% 57 110 30.0% 15 35
$1 34.3% 24 46 47.3% 69 77
ap-values are results of Chi-square tests.
doi:10.1371/journal.pone.0086194.t002
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melanoma patients progressed to stage IV during observation
(p = 0.031).
The median overall survival time according to Kaplan Meier
after development of distant metastases was 9 months and was not
associated with BRAF mutational status according to Kaplan-
Meier (p = 0.521; Figure 2C). There was no difference in overall
survival (p = 0.141) or DMFS (p= 0.251) between 150 patients
with V600E mutations compared to 19 patients with V600K or
V600R mutations.
Survival stratified according to tumor thickness
Next, we separately performed the survival analysis for 239
patients with a tumor thickness not exceeding 1 mm and those 198
with tumor thickness larger than 1 mm (Table 4).
In patients with thin primary melanomas an association with
overall survival was observed for the mitotic rate. The 10-year
survival rate for patients with less than 1 mitosis/mm2 was 98.6%
in contrast to 87.6% for the others (p,0.001); this factor had the
highest impact in Cox regression analysis (HR 17.9; p = 0.016).
The detection of BRAF mutations was likewise significantly
associated with unfavorable survival (p = 0.013; Figure 3A) and
represented an additional independent prognostic factor for
melanoma patients with thin primary tumors (HR 11.6;
p = 0.034). In patients with thick primary melanoma ulceration,
sub-classification according to tumor thickness, rate of mitosis, and
histological subtype were associated with survival but only
ulceration (HR 4.2; p,0.001) and tumor thickness greater than
2 mm (HR 2.5; p= 0.009) or 4 mm (HR 2.8; p= 0.021) remained
independent prognostic factors according to Cox regression
analysis. Tumor BRAF mutations were not associated with survival
(Figure 3B) in these patients with thick primary melanomas.
The difference in DMFS according to the BRAF mutational
status was also limited to patients with tumor thickness of 1 mm or
smaller (p = 0.011) and not evident in those with thicker primary
melanomas (p= 0.745).
Discussion
No prognostic impact of BRAF-V600 mutations on overall
survival was observed for the entire cohort of 437 non-
metastasized melanoma patients in our study. According to Cox
regression analysis, we could reproduce all established prognostic
factors considered in the AJCC classification with mitotic rate,
tumor thickness and ulceration being independently relevant for
prognosis of stage I/II patients [23]. A tumor thickness greater
than 2 mm or 4 mm (HR 4.6; p = 0.010 or HR 4.7; p = 0.035,
respectively) and ulceration (HR=3.6; p,0.001) were the most
important prognostic factors, as already established [24,25].
Our findings are in agreement with four other studies which
investigated the prognostic impact of BRAF-V600 tumor muta-
tions in small cohorts of non-metastasized patients and failed to
report any relevance of the mutational status [10,16–18].
We observed a higher rate of BRAF mutations in patients with
SSM compared to other histopathologic subtypes. This correlation
was also found in a meta-analysis which included 36 prior studies
and additionally described the localization of the primary
melanoma in non-chronically sun-damaged skin as a factor
associated with a high rate of BRAF mutations [26]. In our study,
we did not include data on early-life UV-exposure, which was
reported to correlate with the BRAF mutational rate [27], but a
higher rate of mutations in young patients independent of UV-
exposure was observed by us, as well as by others [7,8].
In contrast to non-metastasized patients, the prognostic
relevance of BRAF mutations has been reported previously for
Figure 2. Univariate survival analysis according to BRAF-V600
mutational status. No differences in overall survival (A) but a trend
for unfavorable distant metastases-free survival (B) was observed in
patients with tumor BRAFmutations. Survival after occurrence of distant
metastasis was not different according to the tumor BRAF mutational
status (C).
doi:10.1371/journal.pone.0086194.g002
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patients with distant metastasis [7,8,11]. In the study of Long et al.,
overall survival after development of distant metastasis was
reduced in BRAF mutant patients, while there was no difference
in DMFS [7]. In contrast, in our study we observed no difference
in stage IV survival according to the mutational status but a strong
trend (p= 0.061) for an impaired DMFS in BRAF mutant patients.
Similar results were reported by Edlundh-Rose et al. who analyzed
214 metastasized patients [12].
In addition to differences in DMFS, the higher mutational rate
in 58 stage I/II patients who developed distant metastases during
follow-up compared to 379 patients without subsequent distant
recurrence provides further evidence that a BRAF-V600 mutation
may indicate an increased risk of developing distant metastasis
(51.7% versus 36.7%; p= 0.031). Lower rates of BRAF-V600
mutations had also been previously reported after analysis of
primary tumors compared to metastasis (Figure 4) but was
explained by the acquisition and accumulation of BRAF mutant
tumor cells during the course of disease [10,17,28]. This
explanation is in contrast to recent publications reporting a high
proportion of patients with consistent mutation patterns when
comparing pairs of primary tumors and metastases of the same
individuals [29,30] and the differences in the rate of BRAF
mutations in primary tumors if stratified according to disease
outcome in the current study.
The conflicting results for DMFS can also be explained by
patient selection in prior studies, which limited the analysis of
DMFS to patients, who had already developed distant metastasis
[7]. In the current study, which represents the largest analysis of
the prognostic impact of BRAF mutations in non-metastasized
melanoma patients thus far, we retrospectively analyzed the BRAF
status in patients who had not been selected on the basis of their
later disease course or outcome. The strong trend for a worse
DMFS in BRAF mutant patients observed in our cohort is
completely lost, if the analysis is restricted to patients who
developed distant metastasis in their later course of disease (data
not shown).
The conflicting results for stage IV survival might also be
explained by a potential patient selection bias. In some prior
retrospective prognostic studies using already available institution-
al data from mutational testing it has to be assumed that the BRAF
V600 status was tested due to the intention to treat with a BRAF-
or MEK inhibitor at least in a subset of patients (e.g. [9]). But in
order to analyze the treatment-unrelated ‘‘natural’’ impact of
BRAF-V600 tumor mutations only patients with confirmed
BRAF-mutations who finally did not receive subsequent inhibitor
treatment can be considered. Reasons among others for
non-treatment with inhibitors in BRAF-V600 mutant patients
could be exclusion criteria in the frame of clinical studies (e.g.
elevated LDH or occurrence of brain metastases), decrease of
performance status or early death due to disease progression.
Therefore these patients might represent a cohort biased towards
worse prognosis.
We included a majority of patients (n = 239) with tumor
thickness of 1 mm or less. In the 7th edition of the AJCC staging
classification, ulceration and mitotic rate are considered for
classification purposes in these patients [31]. Even if prognosis is
generally considered good, between 5% and 10% eventually die
from melanoma [31]. Additional prognostic markers are therefore
desirable for this large subgroup, representing more than 40% of
all stage I/II patients [31]. We showed that BRAF-V600 mutations
in melanoma cells represent a prognostic factor indicating worse
distant metastasis-free and overall survival of non-metastasized
patients with a tumor thickness of 1 mm or less. These are results
of a subgroup analysis and have to be interpreted with caution, as
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it is based on a small number of events. On the other hand the
present study is the first which focused on low risk patients. Only
Shinozaki et al. [17] included a limited number of patients (n = 19)
with a tumor thickness of less than 1 mm, and a selection towards
thick primary melanomas was likewise evident in other previous
studies performed in non-metastatic patients. Our results may
provide a rationale to analyze the prognostic impact of BRAF
mutations in non-metastasized low risk patients in larger studies.
In conclusion, no significant survival differences were found
according to BRAF-V600 tumor mutations in patients with
primary melanoma but an increasing impact of the mutational
status was observed in the subgroup of patients with tumor
thickness of 1 mm or less. A potential role of the mutational status
as a prognostic factor especially in this subgroup needs to be
investigated in larger studies.
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